Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Medartis Holding AG's 3-Year RORE % for the quarter that ended in Dec. 2025 was 62.00%.
The industry rank for Medartis Holding AG's 3-Year RORE % or its related term are showing as below:
XSWX:MED's 3-Year RORE % is ranked better than 88.09% of 781
companies
in the Medical Devices & Instruments industry
Industry Median: -4.27
vs XSWX:MED: 62.00
Medartis Holding AG (XSWX:MED) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Medartis Holding AG 3-Year RORE % Related Terms
Medartis Holding AG 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MED vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Medartis Holding AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Medartis Holding AG (XSWX:MED) has a 3-Year RORE % of 62.00 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medartis Holding AG and its competitors. According to the industry distribution chart, Medartis Holding AG ranks #93 out of 781 companies in the Medical Devices & Instruments industry, placing it in the top 11.9%.
Is Medartis Holding AG's 3-Year RORE % too high?
Medartis Holding AG's current 3-Year RORE % is 62.00. Based on the distribution chart, Medartis Holding AG ranks #93 out of 781 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medartis Holding AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #93 out of 781 companies for 3-Year RORE %. This places Medartis Holding AG in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medartis Holding AG and its competitors. Medartis Holding AG's current 3-Year RORE % is 62.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF106.36, compared to a current price of CHF83.50 — trading 21.5% below its estimated fair value. The current 3-Year RORE % is 62.00. Medartis Holding AG's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current 3-Year RORE % is 62.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF83.50 is trading 21.5% below its estimated GF Value™ of CHF106.36.
GuruFocus considers Medartis Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:MED:
3-Year RORE %: 62.00
GF Value™: CHF106.36 vs. price of CHF83.50 (21.5% below fair value)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
84GF Score
Get the complete analysis for XSWX:MED
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
